2020 Biotech Portfolio Soars 55%, We’re Amazed. Next Up: The Coming Gold Rush.

1. Yep, We Are Absolutely Amazed At The Biotech Stock Review's 2020 Watch List Performance – Especially In The Light Of – Well Everything....
American Brivision

Adding American BriVision (ABVC) $3.30 to Stocks We Expect Double List. $7.00 Price Potential.

Adding to Our 2020 Biotech 5-Pack, 5 Stocks We Expect to Double in 2020 To Put It Mildly, We Are Absolutely Amazed With Our 2020,...

Where is Citius Pharma (CTXR) in the FDA Approval Process?

We have a number of subscribers asking for an update on the FDA approval process for Mino-Lok. In layman's term (assuming approval) the answer...

2020 Biotech Portfolio Soars 55%, We’re Amazed.

1. Yep, We Are Absolutely Amazed At The Biotech Stock Review’s 2020 Watch List Performance – Especially In The Light Of – Well Everything. Our...

Citius (CTXR) CEO Myron Holubiak Live on TV, 1:20 Today, June 30th.

VIDEO: Citius CEO Myron Holubiak to Appear on TD Ameritrade Network's The Watch List with Nicole Petallides LIVE CHART - Live on-air interview to feature Citius...
Citius Pharma

Citius Pharma (CTXR) On The Move.

One Of Our Top 5 Biotech Picks For 2020 Up 23% Yesterday, Indicating Up Another 24% This Morning. Inquiring Minds Want To Know! Citius (a...
Immunomedics, Biotech Stock Review

Immunomedics (IMMU) $33 | Raising Price Potential to $60. American BriVision (ABVC) $3.00 |...

We Are Raising the Price Potential of Immunomedics (IMMU) to $60, Highest on the Street, and Initiating Coverage on Another $3.00 Medical Start-Up American...

Update: Biotech 5 Pack. 5 Biotech Stocks, we Expected to Double in 2020.

No Doubles Yet, But They're Doing Rather Well, Considering Everything. Our Confidence Remains Unwavered. Best Performer up 63%. IN ORDER OF SHARE PRICE..LOW TO HIGH Mitesco...
Immunomedics IMMU, Biotech Stock Review

Immunomedics (IMMU) up 100% Today or $2 Billion in Value.

Again as mentioned a few weeks ago, our bearish market opinion is related to large-caps and large-cap funds and ETF's. If you find a small company whose...

Latest article

Jeffrey Gundlach: Reckoning is Coming.

Jeffrey Edward Gundlach is a businessman, fund manager, and philanthropist. He is the founder of DoubleLine Capital, an investment firm. On 11 November 2020, Gundlach remarked in an interview with...

Who’s the Next Eric Sprott?

To say Eric Sprott has left a legendary mark on the world of mining investment would be an understatement. With a career spanning five...

Perpetua (PPTA) Raises $300 Million.

Not a bad day in Idaho. $300 million banked! We look at the dip as a buying opportunity, as does John Paulson & Co.,...